235 related articles for article (PubMed ID: 38157255)
21. Cuproptosis-Related LncRNA Signature for Predicting Prognosis of Hepatocellular Carcinoma: A Comprehensive Analysis.
Chen Q; Sun T; Wang G; Zhang M; Zhu Y; Shi X; Ding Z
Dis Markers; 2022; 2022():3265212. PubMed ID: 36452343
[TBL] [Abstract][Full Text] [Related]
22. Cuproptosis-related signature for clinical prognosis and immunotherapy sensitivity in hepatocellular carcinoma.
Xu S; Dong K; Gao R; Yang Y; Zhou Y; Luo C; Chen W; Liu SM
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12249-12263. PubMed ID: 37434092
[TBL] [Abstract][Full Text] [Related]
23. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F
Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880
[TBL] [Abstract][Full Text] [Related]
24. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
Yan C; Niu Y; Ma L; Tian L; Ma J
J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
[TBL] [Abstract][Full Text] [Related]
25. Identification of a cuproptosis and copper metabolism gene-related lncRNAs prognostic signature associated with clinical and immunological characteristics of hepatocellular carcinoma.
Yuan W; Xiao JH; Zhang JS; Mao BL; Wang PZ; Wang BL
Front Oncol; 2023; 13():1153353. PubMed ID: 37056336
[TBL] [Abstract][Full Text] [Related]
26. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
Front Immunol; 2022; 13():933241. PubMed ID: 36211378
[TBL] [Abstract][Full Text] [Related]
27. Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma.
Zhang L; Xu J; Chu X; Zhang H; Yao X; Zhang J; Guo Y
BMC Bioinformatics; 2022 Nov; 23(1):485. PubMed ID: 36384423
[TBL] [Abstract][Full Text] [Related]
28. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
Front Genet; 2023; 14():1056000. PubMed ID: 36845390
[No Abstract] [Full Text] [Related]
29. Construction and systematic evaluation of a machine learning-based cuproptosis-related lncRNA score signature to predict the response to immunotherapy in hepatocellular carcinoma.
Lu D; Liao J; Cheng H; Ma Q; Wu F; Xie F; He Y
Front Immunol; 2023; 14():1097075. PubMed ID: 36761763
[TBL] [Abstract][Full Text] [Related]
30. Identification and development of a novel risk model based on cuproptosis-associated RNA methylation regulators for predicting prognosis and characterizing immune status in hepatocellular carcinoma.
Li D; Shi Z; Liu X; Jin S; Chen P; Zhang Y; Chen G; Fan X; Yang J; Lin H
Hepatol Int; 2023 Feb; 17(1):112-130. PubMed ID: 36598701
[TBL] [Abstract][Full Text] [Related]
31. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
[TBL] [Abstract][Full Text] [Related]
32. A novel cuproptosis-related prognostic lncRNA signature for predicting immune and drug therapy response in hepatocellular carcinoma.
Chen S; Liu P; Zhao L; Han P; Liu J; Yang H; Li J
Front Immunol; 2022; 13():954653. PubMed ID: 36189204
[TBL] [Abstract][Full Text] [Related]
33. A novel cuproptosis-related prognostic signature and potential value in HCC immunotherapy.
Wang XX; Wu LH; Ji H; Liu QQ; Deng SZ; Dou QY; Ai L; Pan W; Zhang HM
Front Mol Biosci; 2022; 9():1001788. PubMed ID: 36250008
[No Abstract] [Full Text] [Related]
34. Integrated machine learning and bioinformatic analyses used to construct a copper-induced cell death-related classifier for prognosis and immunotherapeutic response of hepatocellular carcinoma patients.
Zhao S; Chen S; Liu W; Wei S; Wu X; Cui D; Jiang L; Chen S; Wang J
Front Pharmacol; 2023; 14():1188725. PubMed ID: 37266152
[No Abstract] [Full Text] [Related]
35. Prediction of prognosis, immune infiltration, and personalized treatment of hepatocellular carcinoma by analysis of cuproptosis-related long noncoding RNAs and verification
Li S; Zhu Z; Lu J; Cao W; Song F; Xiao C; Zhang P; He Z; Weng J; Xu J
Front Oncol; 2023; 13():1159126. PubMed ID: 37746284
[TBL] [Abstract][Full Text] [Related]
36. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
[TBL] [Abstract][Full Text] [Related]
37. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
38. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
Li Y; Zeng X
Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
[No Abstract] [Full Text] [Related]
39. Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC.
Wang Y; Zhang Y; Wang L; Zhang N; Xu W; Zhou J; Zhao Y; Zhu W; Zhang T; Wang L
Hepatol Int; 2022 Dec; 16(6):1435-1447. PubMed ID: 36065073
[TBL] [Abstract][Full Text] [Related]
40. An 8-gene predicting survival model of hepatocellular carcinoma (HCC) related to pyroptosis and cuproptosis.
Wang H; Wang N; Tang Z; Liu Q; Nie S; Tao W
Hereditas; 2023 Jul; 160(1):30. PubMed ID: 37464443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
